Chimeric antigen receptor (CAR) T cells, T cells that have been genetically engineered to
express a receptor that recognizes a specific antigen, have given rise to breakthroughs in …

As a non-antibody scaffold, monobodies based on the fibronectin type III (FN3) domain
overcome antibody size and complexity while maintaining analogous binding loops …

Background The adoptive transfer of chimeric antigen receptor (CAR)-T cells has emerged
as a potent immunotherapy against some hematological malignancies but not yet for …

Solid tumors that are responsible for more than 85% of cancer death cases need
angiogenesis for their growth and metastasis. Among antiangiogenic therapies, targeting the …

For successful application of chimeric antigen receptor (CAR) T cell therapy in solid tumors,
major hurdles have to be overcome. CAR T cells have to cross the vascular barrier, which is …

Background T cells engineered to express chimeric antigen receptors (CARs) are a novel
modality to treat refractory cancers. The development of CAR T cells against Ewing sarcoma …

Melanoma is among the most lethal forms of cancer, accounting for 80% of deaths despite
comprising just 5% of skin cancer cases. Treatment options remain limited due to the genetic …

Chimeric antigen receptor (CAR) T cells provide a promising approach to the treatment of
hematologic malignancies and solid tumors. Flow cytometry is a powerful analytical …

Introduction Chimeric antigen receptor (CAR) T-cells have emerged as a ground-breaking
therapy for the treatment of hematological malignancies due to their capacity for rapid tumor …

Background The chimeric antigen receptor-expressing T (CAR-T) cells for cancer
immunotherapy have obtained considerable clinical importance. CAR T cells need an …